Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
The Primary endpoint will be improvement in a composite score of histological injury as measured by the NASH Activity Score (NAS).
approximately 12 months from enrollment
Stephen H Caldwell, MD
University of Virginia
United States: Food and Drug Administration
|University of Virginia School of Medicine||Charlottesville, Virginia 22908|